Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Richella C. Ryan, Peter G. Lawlor & Janice M. Walshe. (2010) Cancer of unknown primary: addressing the communicative, ethical and medical challenges in clinical practice – a perspective from palliative care and supportive oncology. Progress in Palliative Care 18:5, pages 291-296.
Read now
Read now
Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Anita Gothelf & Gedske Daugaard. (2010) Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncologica 49:4, pages 423-430.
Read now
Read now
Articles from other publishers (20)
Risako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, Mayumi Homma, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Kiyoshi Yoshimura, Satoshi Wada, Toshiko Yamochi & Takuya Tsunoda. (2023) Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary. Frontiers in Oncology 13.
Crossref
Crossref
Francisco Martinez, Eric Brucks, Janelle Otsuji, Haseeb Mehnoor, Hina Arif-Tiwari, Hani M. Babiker & Alejandro Recio-Boiles. (2021) Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary. JCO Precision Oncology:5, pages 981-987.
Crossref
Crossref
Noemi Laprovitera, Mattia Riefolo, Elisa Porcellini, Giorgio Durante, Ingrid Garajova, Francesco Vasuri, Ariane Aigelsreiter, Nadia Dandachi, Giuseppe Benvenuto, Federico Agostinis, Silvia Sabbioni, Ioana Berindan Neagoe, Chiara Romualdi, Andrea Ardizzoni, Davide Trerè, Martin Pichler, Antonietta D'Errico & Manuela Ferracin. (2021) MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology 15:10, pages 2732-2751.
Crossref
Crossref
Noemi Laprovitera, Mattia Riefolo, Elisa Ambrosini, Christiane Klec, Martin Pichler & Manuela Ferracin. (2021) Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers 13:3, pages 451.
Crossref
Crossref
Alga S Ramos Morales, Jamie K Joy & Daniela M Zbona. (2020) Administration sequence for multi-agent oncolytic regimens. Journal of Oncology Pharmacy Practice 26:4, pages 933-942.
Crossref
Crossref
Stefan Kolling, Ferdinando Ventre, Elena Geuna, Melissa Milan, Alberto Pisacane, Carla Boccaccio, Anna Sapino & Filippo Montemurro. (2020) “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?. Frontiers in Oncology 9.
Crossref
Crossref
Marc-Antoine Benderra, Marius Ilié, Paul Hofman & Christophe Massard. (2016) Prise en charge des carcinomes de primitif inconnu en 2016. Bulletin du Cancer 103:7-8, pages 697-705.
Crossref
Crossref
M. Riihimäki, A. Hemminki, K. Sundquist & K. Hemminki. (2013) Time trends in survival from cancer of unknown primary: Small steps forward. European Journal of Cancer 49:10, pages 2403-2410.
Crossref
Crossref
J Lee, S Hahn, D-W Kim, J Kim, S N Kang, S Y Rha, K B Lee, J-H Kang & B-J Park. (2012) Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. British Journal of Cancer 108:1, pages 39-48.
Crossref
Crossref
M. Stahl & B. Brücher-Encke. (2012) CUP – Internistische Therapie bei ungünstigem RisikoprofilCUP – Systemic treatment in patients with unfavourable prognostic factors. Der Onkologe 19:1, pages 29-35.
Crossref
Crossref
Giulia Maria Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco & Paola Cassoni. (2012) Cancers of unknown primary origin: current perspectives and future therapeutic strategies. Journal of Translational Medicine 10:1.
Crossref
Crossref
Eric Yaovi Amela, Géraldine Lauridant-Philippin, Sophie Cousin, Thomas Ryckewaert, Antoine Adenis & Nicolas Penel. (2012) Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/Hematology 84:2, pages 213-223.
Crossref
Crossref
Christophe Massard, Yohann Loriot & Karim Fizazi. (2011) Carcinomas of an unknown primary origin—diagnosis and treatment. Nature Reviews Clinical Oncology 8:12, pages 701-710.
Crossref
Crossref
C. Natoli, V. Ramazzotti, O. Nappi, P. Giacomini, S. Palmeri, M. Salvatore, M. Landriscina, M. Zilli, P.G. Natali, N. Tinari & S. Iacobelli. (2011) Unknown primary tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:1, pages 13-24.
Crossref
Crossref
Metin Isik, Mehmet M. Seker, Hatice Odabas, Fahriye T. Kos, Dogan Uncu & Nurullah Zengin. (2010) Gemcitabine and cisplatin in patients with carcinoma of unknown primary site. Medical Oncology 28:2, pages 591-596.
Crossref
Crossref
M. Kodaira, S. Takahashi, S. Yamada, K. Ueda, Y. Mishima, K. Takeuchi, N. Yamamoto, Y. Ishikawa, M. Yokoyama, T. Saotome, Y. Terui & K. Hatake. (2010) Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Annals of Oncology 21:6, pages 1163-1167.
Crossref
Crossref
Ivica Pejcic, Svetislav Vrbic, Sladjana Filipovic, Mirjana Scekic, Ivan Petkovic, Ljiljana Pejcic & Nebojsa Djenic. (2010) Significance of serum tumor markers monitoring in carcinomas of unknown primary site. Vojnosanitetski pregled Military Medical and Pharmaceutical Journal of Serbia 67:9, pages 723-731.
Crossref
Crossref
Vassilis Golfinopoulos, George Pentheroudakis, Georgia Salanti, Andreas D. Nearchou, John P.A. Ioannidis & Nicholas Pavlidis. (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. Cancer Treatment Reviews 35:7, pages 570-573.
Crossref
Crossref
George Pentheroudakis, F.A. Greco & Nicholas Pavlidis. (2009) Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews 35:3, pages 221-227.
Crossref
Crossref
K Yonemori, M Ando, M Yunokawa, T Hirata, T Kouno, C Shimizu, K Tamura, N Katsumata, A Hirakawa, K Matsumoto, Y Yamanaka, H Arioka & Y Fujiwara. (2008) Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. British Journal of Cancer 100:1, pages 50-55.
Crossref
Crossref